The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. A final decision is expected in the coming months.
For the first time in decades, more people in the Bronx nearby Montefiore Einstein Comprehensive Cancer Center are being diagnosed with stage 1, versus stage 4 lung cancer.
